For the Inventor, By the Inventor

Enter assignee name

Nijmegen, Netherlands

Synthon Biopharmaceuticals B.v.

USPTO Granted Patents = 11

CIPO Patents = 19

EPO Patents = 9

Trademarks = 19

Forward Citations = 61

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Peter Johannes Goedings (4 out of 5 patents)

Patrick Henry Beusker (3 out of 14 patents)

Rudy Gerardus Elisabeth Coumans (3 out of 16 patents)

4. Gerardus Joseph Andreas Ariaans (3 out of 8 patents)

5. Willem Dokter (2 out of 3 patents)

6. Gijsbertus Franciscus Maria Verheijden (2 out of 6 patents)

7. Declan Thomas Nolan (2 out of 2 patents)

8. Frans Van Dalen (2 out of 11 patents)

9. Alessandro D Santin (2 out of 19 patents)

10. Ronald Christiaan Elgersma (1 out of 6 patents)

11. Johannes Albertus Frederikus Joosten (1 out of 8 patents)

12. Henri Johannes Spijker (1 out of 9 patents)

13. Franciscus Marinus Hendrikus De Groot (1 out of 11 patents)

14. Guy De Roo (1 out of 1 patent)

15. Ruud Martin Verstegen (1 out of 1 patent)

11 patents: Sort by Forward Citations

1. 10603387 - Duocarmycin ADCs showing improved in vivo antitumor activity (2020-03-31),

2. 10407743 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs (2019-09-10),

3. 10266606 - Method for purifying Cys-linked antibody-drug conjugates (2019-04-23),

4. 10092659 - Duocarmycin ADCs for use in treatment of endometrial cancer (2018-10-09),

5. 9890159 - Process for making duocarmycin prodrugs (2018-02-13),

6. 9845338 - Method of purifying an antibody (2017-12-19),

7. 9580501 - Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases (2017-02-28),

8. 9573996 - Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases (2017-02-21),

9. 9427480 - Duocarmycin ADCs for use in treatment of endometrial cancer (2016-08-30),

10. 9421278 - Duocarmycin ADCS showing improved in vivo antitumor activity (2016-08-23),

11. 8716557 - Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants (2014-05-06),

Synthon Biopharmaceuticals is a global research-driven biopharmaceutical company dedicated to delivering high-quality, innovative therapies to patients worldwide. With a focus on developing biosimilars and new biological entities, we aim to make a meaningful impact on healthcare by providing affordable access to life-saving treatments. Our commitment to excellence and patient-centric approach guide our work in advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

11 Patents

#6 in Nijmegen

#563 in Netherlands

#50,159 in the World

Nijmegen, Netherlands

Synthon Biopharmaceuticals B.v.

Forward Citations = 61

48 inventors:

Peter Johannes Goedings (4 out of 5 patents)

Patrick Henry Beusker (3 out of 14 patents)

Rudy Gerardus Elisabeth Coumans (3 out of 16 patents)

4. Gerardus Joseph Andreas Ariaans (3 out of 8 patents)

5. Willem Dokter (2 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…